Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.

The article discusses research being done on the pancreatic safety of incretin-based therapies. It references te study "Incretin-Based Therapy and Risk of Acute Pancreatitis: Nationwide Population-Based Case-Control Study," by R. W. Thomsen et al. in the 2015 issue. Topics discussed include the risk from using glucagon-like peptide 1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors (DPP-4I), the link between DPP-4I and increased AP risk, and the cardiovascular safety trials.